© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Insmed Incorporated (INSM) stock surged +0.98%, trading at $104.47 on NASDAQ, up from the previous close of $103.46. The stock opened at $103.00, fluctuating between $101.75 and $107.49 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 25, 2026 | 103.00 | 107.49 | 101.67 | 104.47 | 4.41M |
| Jun 24, 2026 | 103.40 | 107.20 | 102.31 | 103.46 | 3.11M |
| Jun 23, 2026 | 98.84 | 103.15 | 97.60 | 102.15 | 4.2M |
| Jun 22, 2026 | 95.82 | 99.88 | 95.27 | 98.61 | 4.23M |
| Jun 18, 2026 | 100.11 | 100.25 | 94.00 | 95.80 | 23.34M |
| Jun 17, 2026 | 95.18 | 99.15 | 94.22 | 98.45 | 3.47M |
| Jun 16, 2026 | 97.50 | 98.10 | 93.92 | 95.52 | 3.42M |
| Jun 15, 2026 | 98.85 | 100.17 | 97.04 | 97.46 | 3.79M |
| Jun 12, 2026 | 95.12 | 98.51 | 93.92 | 97.85 | 4.53M |
| Jun 11, 2026 | 92.30 | 98.18 | 91.37 | 96.72 | 5.1M |
| Jun 10, 2026 | 98.28 | 99.25 | 90.39 | 91.88 | 5.39M |
| Jun 09, 2026 | 95.75 | 99.55 | 95.43 | 99.04 | 4.22M |
| Jun 08, 2026 | 94.45 | 96.77 | 92.07 | 94.17 | 4.95M |
| Jun 05, 2026 | 103.78 | 105.00 | 92.81 | 94.22 | 7.95M |
| Jun 04, 2026 | 103.39 | 105.29 | 102.89 | 104.92 | 1.85M |
| Jun 03, 2026 | 102.27 | 105.20 | 101.73 | 103.86 | 2.62M |
| Jun 01, 2026 | 106.09 | 106.79 | 102.81 | 106.03 | 3.36M |
| May 29, 2026 | 107.85 | 108.46 | 106.26 | 106.91 | 4.53M |
| May 28, 2026 | 106.90 | 109.95 | 106.10 | 108.37 | 2.23M |
| May 27, 2026 | 107.80 | 109.78 | 106.04 | 106.40 | 3.09M |
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
| Employees | 1271 |
| Beta | 0.77 |
| Sales or Revenue | $305.21M |
| 5Y Sales Change% | 15.981% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |